Scalper1 News
Juno Therapeutics on Tuesday filed terms for its IPO, setting it up to be the largest biotech offering by market value this year. Juno is developing novel cellular immunotherapies for the treatment of cancers such as leukemia and lymphoma. It uses human T cells as therapeutics to recognize and kill cancer cells. The technology has the potential to revolutionize the way cancer is treated, according to the company. Seattle-based Juno plans to raise Scalper1 News
Scalper1 News